Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054535 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00054535: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00054535 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054535, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant fowlpox-tyrosinase vaccine
- BIOLOGICAL vaccinia-tyrosinase vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00054535 record still lists
NCT00054535 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which aldesleukin is the first listed.
NCT00054535 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00054535 about?
NCT00054535 is a clinical study titled "Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who hav...
What is the current status of trial NCT00054535?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00054535?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant fowlpox-tyrosinase vaccine (BIOLOGICAL), vaccinia-tyrosinase vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00054535?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia